Who is on it, and how far along Every drug ChEMBL records acting on FGFR1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved4 Nintedanib Nintedanib SponsorCSPC Pharmaceutical Group ModalitySmall molecule ActionInhibitor Open trials26 Erdafitinib Erdafitinib SponsorJohnson & Johnson ModalitySmall molecule ActionInhibitor Open trials19 Futibatinib Futibatinib SponsorTaiho Oncology ModalitySmall molecule ActionInhibitor Open trials14 Infigratinib Infigratinib SponsorHelsinn Healthcare ModalitySmall molecule ActionInhibitor Open trials5 Phase 33 Brivanib Brivanib SponsorBristol-Myers Squibb ModalitySmall molecule ActionInhibitor Open trials0 Brivanib alaninate Brivanib alaninate SponsorBristol-Myers Squibb ModalitySmall molecule ActionInhibitor Open trials0 Orantinib Orantinib SponsorTaiho Pharmaceutical Co., Ltd. ModalitySmall molecule ActionInhibitor Open trials0 Phase 25 Derazantinib Derazantinib SponsorBasilea Pharmaceutica ModalitySmall molecule ActionInhibitor Open trials1 Fexagratinib Fexagratinib SponsorAstraZeneca Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials1 Rogaratinib Rogaratinib SponsorBayer ModalitySmall molecule ActionInhibitor Open trials1 ENMD-981693 ENMD-981693 SponsorCASI Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials0 XL-999 XL-999 SponsorSymphony Evolution, Inc. ModalitySmall molecule ActionInhibitor Open trials0 Phase 12 CP-459632 CP-459632 SponsorNot known ModalityOther ActionInhibitor Open trials0 LY-2874455 LY-2874455 SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Fibroblast growth factor receptor inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 32 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Yangyin Qingfei Decoction for Radiation Pneumonitis Prevention Nintedanib Phase 2 Not yet recruiting The First Affiliated Hospital of Zhejiang Chinese Medical University Nov 17, 2026 A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis Nintedanib Phase 2 Not yet recruiting CSPC-NBP Pharmaceutical Co., Ltd. Nov 12, 2026 Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib Phase 3 Not yet recruiting UNICANCER Aug 4, 2026 Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis Nintedanib — Not yet recruiting Bristol-Myers Squibb Jul 23, 2026 Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Futibatinib Phase 3 Recruiting Taiho Pharmaceutical Co., Ltd. Jul 17, 2026 Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis Nintedanib Phase 2 Recruiting Mannkind Corporation Jul 1, 2026 Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Futibatinib Phase 2 Not yet recruiting Northwestern University Jun 10, 2026 A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension Nintedanib — Not yet recruiting Cosmos Rx, Inc May 29, 2026 Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Futibatinib Phase 1 Recruiting Northwestern University May 18, 2026 Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) Nintedanib Phase 2 Not yet recruiting First Affiliated Hospital of Wenzhou Medical University May 13, 2026 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis Nintedanib Phase 3 Not yet recruiting Haisco Pharmaceutical Group Co., Ltd. Apr 9, 2026 Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD Nintedanib — Recruiting University of Patras Mar 24, 2026 Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia Infigratinib Phase 2 Enrolling by invitation QED Therapeutics, a BridgeBio company Feb 6, 2026 Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) Infigratinib Phase 2 Recruiting QED Therapeutics, a BridgeBio company Sep 11, 2025 Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study) Infigratinib Phase 3 Active, not recruiting Kyowa Kirin Co., Ltd. Apr 13, 2025 A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer Erdafitinib Phase 3 Recruiting Janssen Research & Development, LLC Apr 9, 2025 An Interventional Study of Infigratinib in Children With Hypochondroplasia Infigratinib Phase 2 / Phase 3 Enrolling by invitation QED Therapeutics, a BridgeBio company Mar 12, 2025 Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities Futibatinib Phase 2 Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Dec 9, 2024 Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Erdafitinib Phase 2 Not yet recruiting Peking University Shenzhen Hospital Nov 18, 2024 Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations Erdafitinib Phase 2 Recruiting Spanish Oncology Genito-Urinary Group Jul 22, 2024 Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. Futibatinib Phase 2 / Phase 3 Active, not recruiting Taiho Oncology, Inc. Jul 18, 2024 Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) Erdafitinib Phase 2 Active, not recruiting National Cancer Institute (NCI) Apr 8, 2024 A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer Erdafitinib Phase 3 Recruiting Janssen Research & Development, LLC Mar 20, 2024 Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) Erdafitinib Phase 2 Active, not recruiting National Cancer Institute (NCI) Mar 13, 2024 Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Futibatinib Phase 2 Recruiting Yuanquan Yang Feb 16, 2024 Drug Screening Using IMD in Bladder Cancer Erdafitinib Early phase 1 Enrolling by invitation Brigham and Women's Hospital Jan 12, 2024 A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing Erdafitinib — Active, not recruiting Bernie Eigl Nov 13, 2023 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Futibatinib Phase 2 Active, not recruiting Taiho Oncology, Inc. Jul 14, 2023 Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements Derazantinib Phase 2 Active, not recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Jan 3, 2022 Extension Study of Infigratinib in Children With Achondroplasia (ACH) Infigratinib Phase 2 Enrolling by invitation QED Therapeutics, a BridgeBio company Dec 6, 2021 Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) Rogaratinib Phase 2 Active, not recruiting National Cancer Institute (NCI) Oct 22, 2020 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Fexagratinib Phase 2 Active, not recruiting National Cancer Institute (NCI) Jun 8, 2015
Show all 32Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095217 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets